Atopic Dermatitis

A regimen of dupilumab and a corticosteroid may be beneficial for preteen children with severe atopic dermatitis, according to findings presented at the American Academy of Dermatology virtual meeting.

The FDA has accepted a biologics license application for tralokinumab for the treatment of moderate to severe atopic dermatitis in adults, Leo Pharma announced in a press release.

Subcutaneous nemolizumab combined with topical agents reduced pruritus in Japanese patients with atopic dermatitis, according to phase 3 trial results published in the New England Journal of Medicine.

The use of abrocitinib in the treatment of moderate to severe atopic dermatitis was beneficial while lowering the risk for adverse events, according to findings presented at the American Academy of Dermatology virtual meeting.

The Dupixent prefilled pen has been approved by the FDA for all Dupixent indications in patients aged 12 years and older, Regeneron announced in a press release.

A study presented at the American Academy of Dermatology virtual meeting associated several risk factors for herpes zoster hospitalization in those with chronic inflammatory skin diseases.

Tralokinumab 300 mg showed significant improvements in pruritus and quality of life in atopic dermatitis patients in three phase 3 trials, according presentations at the American Academy of Dermatology virtual meeting.

Kymera Therapeutics has initiated a non-interventional trial evaluating IRAK4 expression in hidradenitis suppurativa and atopic dermatitis, according to a press release.

Dupixent has been approved by the FDA for the treatment of moderate to severe atopic dermatitis in children aged 6 to 11 years, Regeneron Pharmaceuticals and Sanofi announced in a press release.

Dupilumab showed rapid improvement in itch in patients with moderate to severe atopic dermatitis, according to an analysis of four phase 3 trials.